Predictive Factors Affecting the Success of Nephrectomy for the Treatment of Nephrogenic Hypertension: Multicenter Study

2021 ◽  
pp. 1-6
Author(s):  
Ediz Vuruskan ◽  
Hakan Ercil ◽  
Umut Unal ◽  
Ergun Alma ◽  
Hakan Anil ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Partial Response ◽  
Medical Treatment ◽  
Predictive Factors ◽  
Treatment Success ◽  
Complete Response ◽  
Response To Treatment ◽  
Factors Affecting ◽  
Success Of Treatment ◽  
Functioning Kidney

<b><i>Introduction:</i></b> The aim of our study is to evaluate the predictive factors affecting the success of treatment with nephrectomy in patients with poorly functioning kidney and nephrogenic hypertension. <b><i>Methods:</i></b> Data for patients who underwent nephrectomy with a diagnosis of nephrogenic hypertension in 3 centers between May 2010 and January 2020 were analyzed. In the postoperative period, if the blood pressure (BP) was below 140/90 mm Hg without medical treatment, it was accepted as complete response; if the arterial BP was below 140/90 mm Hg with medical treatment or less medication, it was accepted as partial response; and if BP did not decrease to normal values, it was accepted as unresponsive. Demographic characteristics, duration of hypertension, preoperative and postoperative BP values, and presence of metabolic syndrome were statistically evaluated. <b><i>Results:</i></b> Our study consisted of 91 patients with a mean preoperative hypertension duration of 23.3 ± 12.1 months. Among patients, 42 (46.2%) had complete response, 18 (19.8%) had partial response, and 31 (34.0%) had no response. Preoperative systolic and diastolic BP values were not effective on treatment success (<i>p</i> = 0.071, <i>p</i> = 0.973, respectively), but the increase in age and hypertension duration (<i>p</i> = 0.030 and <i>p</i> &#x3c; 0.001, respectively) and the presence of metabolic syndrome (<i>p</i> = 0.002) significantly decreased the complete response rates. <b><i>Conclusions:</i></b> Preoperative hypertension duration, advanced age, and presence of metabolic syndrome are predictive factors affecting the response to treatment in patients who undergo nephrectomy due to nephrogenic hypertension.

Possible immunologic predictors of the PD-1/PD-L1 checkpoint inhibitors' efficiency in lung cancer patients.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e21035-e21035
Author(s):  
Elena Yu. Zlatnik ◽  
Oleg I. Kit ◽  
Elena S. Bondarenko ◽  
Aleksandr B. Sagakyants ◽  
Maria A. Teplyakova ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Partial Response ◽  
Checkpoint Inhibitors ◽  
Complete Response ◽  
Response To Treatment ◽  
Cell Mediated Immunity ◽  
Initial Amount ◽  
Lung Cancer Patients ◽  
Effect Of Therapy ◽  
Check Point Inhibitors

e21035 Background: Immunotherapy with PD-1/PD-L1 check-point inhibitors (CPI) is a new trend in oncology. Their effect significantly depends on the patients` immune status. The aim of the study was to search the immunologic parameters of lung cancer (LC) patients receiving immunotherapy as factors that could predict their effect. Methods: 20 patients (12 male and 8 female) with LC had adenocarcinoma – 15 (75%), squamous cell carcinoma – 5 (25%). PD-1/PD-L1 CPI were used: 9 patients received atezolizumab (43%), 9 (43%) – pembrolizumab and 3 (14%) – nivolumab. The effect of therapy was evaluated according to imRECIST v.1.1. Factors of cell-mediated immunity were assessed by flow cytometry before treatment including immunotherapy. CD8+CD279+, CD4+CD279+, TLR2, TLR4, TLR3, TLR8 were studied. Results: Complete response was observed in 2 (9%) patients, partial response in 5 (24%), stabilization in 4 (19%) and progression in 8 (38%). In one patient the treatment was cancelled due to the development of immune-mediated complication (Guillain-Barre syndrome). The factors studied varied depending on different effect. In cases of LC stabilization/progression the initial amount of CD8+CD279+ cells were twice lower than in cases with complete/partial response. In the first group CD8+CD279+ cells` level before the treatment was 0,1-3,4%, while in the other group 4,1-9% (7,0±1,16%). In patients with stabilization/progression CD4+CD279+ cells` level before the immunotherapy was 0,1-3,3 and in patients with response to treatment 1,4-7,8% (3,4±0,8%) of total CD4+ lymphocytes. Besides, the LC patients with different effect of treatment had different initial amount of CD4+ Tem cells: stable response to CPI developed in patients with their higher levels (40,8±3,9%) vs 15,3±3,9% in cases of tumor progression (p < 0.05). Initial high expression of TLR2 and TLR4 as well as low expression of TLR3 and TLR8 on monocytes in patients with response to immunotherapy suggests the contribution of innate immunity to its effect. Conclusions: Complete or partial response should be expected in cases of initially high per cent of T lymphocytes (CD4+, CD8+) CD4+ Tem cells and TLR2+, TLR4+ as well as low amount of TLR3+ and TLR8+ monocytes. These factors should be studied in future as predictive factors for effectiveness of CPI.

scholarly journals The Efficacy and Safety of Rituximab in a Patient with Rheumatoid Spondylitis

2013 ◽  
Vol 2013 ◽  
pp. 1-4
Author(s):  
Şenol Kobak ◽  
Ahmet Karaarslan ◽  
Fahrettin Oksel
Keyword(s):  
Rheumatoid Arthritis ◽  
Ankylosing Spondylitis ◽  
Connective Tissue ◽  
Partial Response ◽  
Connective Tissue Disease ◽  
Complete Response ◽  
Response To Treatment ◽  
Tnf Alpha ◽  
Efficacy And Safety ◽  
Proven Efficacy

Rheumatoid arthritis (RA) is considered as a connective tissue disease while ankylosing spondylitis (AS) is a prototype of spondyloarthritis. These diseases are seen concomitantly only very rarely. Also, rituximab has proven efficacy in the treatment of RA while its role in the treatment of AS is unclear. In this presentation, the concomitant presence of RA and AS in a 43-year-old male patient as well as the efficacy and safety of rituximab is discussed. Rituximab was given due to lack of response to treatment with anti-TNF-alpha. Evaluations made at the 6th and 12th months of treatment showed complete response for RA and partial response for AS.

Clinical Profile and Treatment Outcome in 92 Patients with AL Amyloidosis Associated with IgM Paraproteinaemia.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 3498-3498
Author(s):  
Ashutosh D. Wechalekar ◽  
Hugh J.B. Goodman ◽  
Julian D. Gillmore ◽  
Helen J. Lachmann ◽  
Mark Offer ◽  
...  
Keyword(s):  
Overall Survival ◽  
Treatment Outcome ◽  
Partial Response ◽  
Lymph Nodes ◽  
Complete Response ◽  
Response To Treatment ◽  
Plasma Cell Dyscrasia ◽  
Al Amyloidosis ◽  
Low Grade ◽  
Haematological Response

Abstract Most patients with AL amyloidosis (AL) have a subtle underlying plasma cell dyscrasia but IgM paraproteinaemia is rare. IgM paraproteinaemia is usually associated with low grade non-Hodgkins lymphoma (NHL) or lymphoplasmacytic lymphoma (LPL)/Waldenstroms macroglobulinaemia(WM) and only rarely with a plasma cell dyscrasia. The profile of AL amyloidosis associated with IgM paraproteinaemia remains poorly studied and the treatment outcome is not well known. We report the clinical profile and outcome of 92 patients with IgM associated AL amyloidosis seen at the National Amyloidosis Centre, UK. Patients were selected by the presence of an IgM paraprotein and absence of any other monoclonal protein in the serum or urine by electrophoresis or immunofixation. There were 68 males and 34 females with a median age 69 yrs (range 50–89). The underlying diseases were WM/LPL in 25 (28%), non specified low grade NHL in 17 (18%), myeloma, non-specified MGUS and CLL in 2 (2.1%) each and uncharacterized in the rest. The median number of organs involved was 2, including renal 56%, heart 32%, liver 41%, lymph nodes 16%. Amyloid was localized only to lymph nodes in 5 (5.5%) patients. The median IgM level was 9g/l (range immunofixation positive to 60g/l). The median follow-up was 19mo (2.4–186). A total of 83 patients received chemotherapy. All patients were evaluable for survival but only 60% were evaluable for haematological response. Responses were defined as complete response (CR) - sustained normalisation of sFLC (serum free light chains) ratio, partial response (PR) - sustained ≥50% reduction in pre-treatment clonal isotype and no response - &lt;50% sFLC reduction or rise in sFLC. The treatments were: oral chlorambucil 18 (19.5%), intermediate dose melphalan (IDM) or VAD 9 (9.7%) each, oral cyclophosphamide 5 (5.4%), oral melphalan or a thalidomide based combination in 3 (3.2%) each, CHOP or single agent fludarabine in 2 (2.1%) each, CVP, fludarabine plus cyclophosphamide (FC), FC plus rituximab (FCR), idarubicin plus dexamethasone or CCNU plus dexamethasone in 1 (1%) each. Due to the small numbers in each group, all patients were analyzed as a single cohort. Only 1 (1%) patient achieved a complete response (CR), 14 (30%) had a partial response (PR), 31 (67%) had no response. The median overall survival was 4.1 years. The responders (CR+PR) had a significantly better overall survival (median not reached; p&lt;0.017) compared to the non-responders (median 3.1 years). The median survival with chlorambucil, VAD or IDM was 8 yrs, 1.4 yrs and 5.1 yrs respectively. Significant factors affecting overall survival were response to treatment, cardiac, renal, liver involvement and IgM level. In summary, the presenting features of IgM associated AL are similar to AL with non-IgM paraproteins, though lymph node involvement is more common. The response to treatment is very poor. There is no consensus about the best chemotherapy regime. The only patient who had a CR was treated with FCR. There is a significant improvement in survival for patients responding to treatment. Antibody based combination chemotherapy may help to improve the haematological response to treatment and improve survival.

Medicare compared with private insurance for the treatment of cancer.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e19033-e19033
Author(s):  
Phillip Martinez-Knouse ◽  
Christie Hancock ◽  
Edward Nabrinsky ◽  
Timothy M. Lestingi ◽  
Jacob D. Bitran
Keyword(s):  
Partial Response ◽  
Retrospective Analysis ◽  
Private Insurance ◽  
Complete Response ◽  
Response To Treatment ◽  
Insurance Status ◽  
Breast Cancers ◽  
Lung Cancers ◽  
Metastatic Setting ◽  
Tumor Types

e19033 Background: Insurance status impacts access to cancer care and outcomes of cancer patients. Patients who are uninsured and those who are insured by Medicaid are less likely to receive cancer screening, more likely to present at later stages of disease, and more likely to die from cancer compared to those who are privately insured. It is unclear whether patients insured by Medicare have different outcomes than patients with private insurance. Methods: We undertook a retrospective analysis of patients treated in our practice from January 1, 2019 to March 31, 2019. Outcomes of solid tumor patients were tracked after treatment in the neoadjuvant or metastatic setting. Patients were stratified by their insurance status and we then compared treatment outcomes of patients with private insurance to those with Medicare. Results: We treated 86 patients from January 1, 2019 to March 31, 2019 including 63 women and 23 men with a median age of 62 years (range 22-88 years). Several types of malignancies were represented including 21 gynecologic cancers, 17 breast cancers, 11 lung cancers, 10 melanomas, 10 gastrointenstinal cancers, 7 lymphomas, 5 genitourinary cancers, and 5 other tumor types. Among our population, 48 patients had private insurance and 38 had Medicare. Thirty-four patients achieved either a complete response (CR) or partial response (PR), 24 with CR and 10 with PR. Of those who achieved a CR, 11 had Medicare and 14 had private insurance. Among those who achieved a PR, 5 had Medicare and 5 had private insurance. Conclusions: In this retrospective analysis, insurance type did not predict likelihood of achieving a complete or partial response to treatment. Other investigators have suggested that patients with Medicare have poorer outcomes than those with private insurance. One potential explanation for the discrepancy between their data and ours is that we have dedicated system designed to accelerate pre-certifications. Additional investigation is warranted to better understand these trends.

Persistent neck disease after chemoradiation for head and neck squamous cell carcinoma

2012 ◽  
Vol 126 (11) ◽  
pp. 1121-1126 ◽  
Author(s):  
J G Sanders ◽  
K G Smith ◽  
M B Jameson ◽  
C de Groot ◽  
J White
Keyword(s):  
Squamous Cell Carcinoma ◽  
Partial Response ◽  
Cell Carcinoma ◽  
Neck Dissection ◽  
Digestive Tract ◽  
Squamous Cell ◽  
Retrospective Chart Review ◽  
Complete Response ◽  
Response To Treatment ◽  
Neck Disease

AbstractObjective:This study aimed to identify the incidence of residual viable neck disease in patients with mucosal squamous cell carcinoma of the upper aero-digestive tract, following primary chemoradiation at a tertiary centre.Study design:Retrospective review.Methods:Retrospective chart review of patients treated with primary chemoradiation for squamous cell carcinoma of the aero-digestive tract between August 2001 and August 2008. Neck status pre- and post-treatment was the primary focus.Results:Forty-two patients with node-positive disease prior to chemoradiation were included. Thirty-seven (88.1 per cent) achieved complete response to treatment: no patient in this group underwent neck dissection, five died due to recurrence at the primary site or distant metastasis, and none suffered neck recurrence. Five (11.9 per cent) patients achieved partial response to chemoradiation and underwent neck dissection; viable tumour was found in one patient.Conclusion:Our data support conservative management of the neck in patients with complete response to chemoradiation, and consolidation neck dissection in patients with partial response.

scholarly journals Evaluation of risk factors predicting surgical treatment in tuboovarian abscess cases

2019 ◽  
Vol 6 (10) ◽  
pp. 235-240
Author(s):  
Bora Çoşkun ◽  
Coşkun Şimşir
Keyword(s):  
Medical Treatment ◽  
Predictive Factors ◽  
Success Rates ◽  
Laboratory Findings ◽  
Factors Affecting ◽  
Neutrophil Lymphocyte Ratio ◽  
Treatment Regimens ◽  
Tuboovarian Abscess ◽  
Retrospective Clinical Study ◽  
Wbc Count

Objective:  The main outcome measure of the present study was to find out the predictive factors affecting the need for surgery in patients diagnosed with tuboovarian abscess (TOA). We also examined the success of different medical treatment regimens in those patients. Material and Methods: This was a retrospective clinical study performed on 96 TOA patients who were treated in the current hospital between August 2015 and August 2019. All patients underwent physical examination and ultrasonographic imaging with some laboratory tests to investigate the presence of TOA. Two different medical treatment regimens were administered as recommended by the international guidelines after the initial diagnoses. Patients with worsening clinical and/or laboratory findings and/or who did not respond to medical treatment were taken to surgery. Predictive factors for surgical intervention and success rates of medical treatment regimens were evaluated. Results: White blood cell (WBC) levels≥ 16000 and abscess size≥ 7 cm was strongly correlated with the requirement for surgery. The 94 patients received the Regimen 1. Six patients underwent surgery urgently when they were under medical treatment. Regimen 1 failed in 21 (22.34 %) patients out of 94, Regimen 2 was shifted to.  Six patients (28.5%) out of 21 underwent surgery because of treatment failure with Regimen 2. Recovery was achieved in the remaining 15 (71.4%) patients. Conclusion: The success of medical TOA treatment was found to be high. Therefore, medical treatment can be applied first, except in case of acute abdomen. It was found that WBC and abscess diameter in patients with TOA in admission were the most important factors affecting the need for surgery. The factors affecting the duration of medical treatment were found to be age, WBC count, CRP (C-Reactive Protein), ESR (Erythrocyte Sedimentation Rate) and NLR (Neutrophil/Lymphocyte Ratio) levels.

scholarly journals Role of laparoscopic nephrectomy for refractory hypertension in poorly functioning kidneys

2011 ◽  
Vol 93 (1) ◽  
pp. 25-26 ◽  
Author(s):  
Oussama Elhage ◽  
Arun Sahai ◽  
Ben Challacombe ◽  
Declan Murphy ◽  
John Scoble ◽  
...  
Keyword(s):  
Partial Response ◽  
Detrimental Effect ◽  
Antihypertensive Drugs ◽  
Complete Response ◽  
Medical Problem ◽  
Laparoscopic Nephrectomy ◽  
Refractory Hypertension ◽  
Small Risk ◽  
Functioning Kidney

INTRODUCTION Hypertension is a common medical problem mainly treated by effective antihypertensive drugs. Persistent hypertension can be difficult to manage and have detrimental effect on vital organs. Nephrectomy of poorly functioning kidneys may be indicated in a minority of such cases. PATIENTS AND METHODS We performed laparoscopic nephrectomy on 12 patients with refractory hypertension. RESULTS Eight had complete response, three had partial response and one had no response. CONCLUSIONS Laparoscopic nephrectomy has a role in carefully selected adult patients with refractory hypertension due to non-functioning kidney. Patients need to understand the surgical risks as well as the small risk of failure to treat hypertension.

Achievement of Complete Response Is Important for Longer Overall Survival in Patients with Newly Diagnosed Myeloma: A Single-Institutional Study

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 5115-5115
Author(s):  
Kanichi Iwama ◽  
Tomotaka Ugai ◽  
Hiroki Sugihara ◽  
Masayuki Yamakura ◽  
Masami Takeuchi ◽  
...  
Keyword(s):  
Overall Survival ◽  
Partial Response ◽  
Complete Response ◽  
Novel Agents ◽  
Response To Treatment ◽  
Prognostic Impact ◽  
Female Ratio ◽  
Best Response ◽  
The Impact

Abstract Abstract 5115 INTRODUCTION. Even with the introduction of novel therapeutic agents, including thalidomide, bortezomib, and lenalidomide, multiple myeloma (MM) is an incurable disease. Deeper responses, such as complete response (CR) and very good partial response (VGPR), are major goals of treatment to obtain long-term overall response (OS) and progression-free response (PSF) in patients with MM. Recent large randomized retrospective studies also suggested improved OS and PFS in patients who achieved deeper responses. However, the prognostic impact of achieving CR or VGPR remains controversial. In addition, these studies included selected patients that may not be representative of the general population. Therefore, we analyzed cases in our database to evaluate the impact of treatment response on the outcome of consecutive patients with symptomatic MM who were treated with chemotherapeutic regimens containing novel agents over the past 6 years at our institution in Kamogawa City, Japan. PATIENTS AND METHODS. We included 97 consecutive patients treated at our institution between April 2005 and May 2011. The study population consisted of 56 male and 41 female patients with a median age of 70 years old (range: 45 −90). Due to the rapid changes in treatment modality and government approval of novel agents in myeloma during this period, initial treatment could not be uniformly categorized, but all patients received chemotherapy regimens containing at least one novel agent, including thalidomide, bortezomib, and lenalidomide. These patients were thought to be more representative of the general myeloma population. Seventy-seven (79.4%), 27 (38.6%), and 55 (56.7%) patients received bortezomib-, lenalidomide-, and thalidomide-containing regimens, respectively. Treatment responses were assessed using the International Myeloma Working Group (IMWG) criteria with minor modifications, and the best response to treatment during the course of disease was evaluated. Immunofixation test and serum free light chain measurements were performed for confirmation of CR and stringent CR. OS was calculated from the time of diagnosis until the date of death from any cause or the date on which the patient was last known to be alive. Univariate and multivariate analyses were performed for the following variables: age at diagnosis, International Staging System (ISS), and best response achieved. RESULT. The median age of patients was 71 y.o. (range: 49 −90 y.o.), and the male to female ratio was 56:41. The best responses to treatment were as follows: CR was obtained in 19 cases (19.6%), VGPR in 29 (29.9%), partial response (PR) in 34 (35.0%), and stable disease (SD) or less in 15 (15.4%). Baseline characteristics according to best response achieved in patients who achieved CR, VGPR, PR, and SD or less were similar among the patients ≥70 y.o. vs. ≤70 y.o. Patients' age has no impact on the response to treatment. With a median follow-up of 25 months, Kaplan–Meier estimated 3-year and 5-year overall survival (OS) rates were 67.2% and 35.0%, respectively. The 3- and 5-year OS were 100% in patients with CR, which were significantly superior in patients with VGPR (3-y 70%, 5-y 55.0%) and PR (3-y 60%, 5-y 23.0%). The 3- and 5-year OS were not significantly different between patients with VGPR and PR. Normalization of FLC kappa/Lambda ratio was observed in 15 of 19 (80%) patients with CR, 15 of 29 (51%) with VGPR, 4 of 34 (6.6%) in PR, and in none of 15 (0%) in SD or less. Patients who showed normalization of FLC kappa/Lambda ratio had significant OS benefit compared to those who did not. Proportional hazard Cox models showed that patients with ISS stage I/II had better 5-year OS rate compared to patients with stage III (51%; 20%, P = 0.005). However, there was no association between ISS stage and achievement of CR. CONCLUSION. The results of the present study highlighted the importance of achieving CR, not PR or VGPR, and normalization of FLC kappa/Lambda ratio for obtaining long-term OS in patients with MM regardless of age or ISS stage. Disclosures: No relevant conflicts of interest to declare.

scholarly journals Success of Using Iodopovidone as a Sclerosing Agent for Chemical Pleurodesis in a Tertiary Care Center: A Descriptive Cross-Sectional Study

2021 ◽  
Vol 59 (233) ◽  
Author(s):  
Deebya Raj Mishra ◽  
Narendra Bhatta ◽  
Puru Koirala ◽  
Bhupendra Shah ◽  
Bidesh Bista ◽  
...  
Keyword(s):  
Pleural Effusion ◽  
Partial Response ◽  
Spontaneous Pneumothorax ◽  
Malignant Pleural Effusion ◽  
Treatment Success ◽  
Tertiary Care ◽  
Complete Response ◽  
Ease Of Use ◽  
High Rate ◽  
Sclerosing Agent

Introduction: Pleurodesis is a procedure to achieve symphysis between the two layers of pleura aimed at preventing the accumulation of either air or fluid in the pleural space. In Nepal, intrapleural instillation of the chemical sclerosing agent is more commonly done as thoracoscopy facility is not easily available. However, iodopovidone is rarely used for this purpose in Nepal. The study aims to find the prevalence of success using iodopovidone as the chemical sclerosing agent. Methods: The study included cases undergoing pleurodesis over a two-year period. The clinicodemographic data, diagnosis, treatment effect and treatment response were analyzed. The treatmentresponse was graded as Treatment Success (Complete Response or Partial Response) and TreatmentFailure. Results: Pleurodesis was done in a total of 54 cases. Of those, 39 cases were Secondary SpontaneousPneumothorax, 11 were Malignant Pleural Effusion, 3 were Primary Spontaneous Pneumothorax,and 1 was a case of Hepatic Hydrothorax. Among Secondary Spontaneous Pneumothorax, Pleurodesis was successful in 37 (95%) out of 39 cases, with 35 (90%) having a Complete Response and 2 (5%)having a Partial Response while 2 (5%) had Treatment failure. Among Malignant Pleural Effusion,treatment success was achieved in 6 (55%) out of 11, whereas 5 (45%) failed the treatment. The commonest complication was burning sensation, and the commonest pain scale was “distressing.” Conclusions: This study highlights the safety and ease of use of iodopovidone as an agent forchemical pleurodesis. It confirms the high rate of success of pleurodesis in cases of pneumothoraxas found in other studies. In contrast, the success rate is understandably lower in cases of MalignantPleural effusion.

scholarly journals Soluble Mesothelin-Related Peptides Levels in Patients with Malignant Mesothelioma

2012 ◽  
Vol 32 (2) ◽  
pp. 123-131 ◽  
Author(s):  
Alenka Franko ◽  
Vita Dolzan ◽  
Viljem Kovac ◽  
Niko Arneric ◽  
Metoda Dodic-Fikfak
Keyword(s):  
Partial Response ◽  
Tumor Marker ◽  
Malignant Mesothelioma ◽  
Stable Disease ◽  
Progressive Disease ◽  
Tumor Response ◽  
Complete Response ◽  
Response To Treatment ◽  
Blood Samples ◽  
Pre Treatment

Soluble mesothelin-related peptides (SMRP) are a potential tumor marker for malignant mesothelioma. The aim of this study was to determine the differences in SMRP levels in patients with malignant mesothelioma before treatment and in various responses to treatment and to investigate whether SMRP level could be useful in evaluating tumor response to treatment. The study included patients with malignant mesothelioma treated at the Institute of Oncology Ljubljana between March 2007 and December 2009. Blood samples were collected before treatment and/or in various responses to treatment. SMRP levels were determined using ELISA assay based upon a combination of two monoclonal antibodies. Mann-Whitney test was used to determine the differences in SMRP levels in various responses to treatment.Median SMRP was 2.80 nmol/L (range 0.00–34.80) before treatment, 0.00 nmol/L (range 0.00–0.00) in complete response, 0.48 nmol/L (range 0.00–4.40) in partial response, 1.65 nmol/L (range 0.00–20.71) in stable disease and 7.15 nmol/L (range 0.44–31.56) in progressive disease. Pre-treatment SMRP levels were significantly higher than in stable disease, partial response and complete response (p=0.006), as were SMRP levels in progressive disease compared to stable disease, partial response and complete response (p= 0.006), as were SMRP levels in progressive disease compared to stable disease, partial response and complete response (p< 0.001).Our findings suggest that SMRP may be a useful tumor marker for detecting the progression of malignant mesothelioma and evaluating tumor response to treatment.

Sign in / Sign up

Export Citation Format

Share Document